It's all about the heart: Di­a­betes ma­jor No­vo Nordisk bets $725M up­front to buy car­dio-fo­cused As­traZeneca spin­off

No­vo Nordisk’s itch to ex­pand its reach be­yond its main­stay di­a­betes busi­ness has man­i­fest­ed in the com­pa­ny test­ing some of its ex­ist­ing treat­ments for use …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.